Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michail Kokkorakis

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|February 14, 2026
Long-term Risk of Prediabetes and Type 2 Diabetes Following SARS-CoV-2 Infection: A Nationwide Cohort StudyFilippos Anagnostakis, Michail Kokkorakis
Metabolism: Clinical and Experimental|October 31, 2024
The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservationKonstantinos Stefanakis, Michail Kokkorakis, Christos S Mantzoros
International Journal of Molecular Sciences|June 10, 2023
Impact of Solute Carrier Transporters in Glioma Pathology: A Comprehensive ReviewFilippos Anagnostakis, Michail Kokkorakis, Mariam Markouli, et al.
Metabolism: Clinical and Experimental|September 9, 2023
Milestones in the journey towards addressing obesity; Past trials and triumphs, recent breakthroughs, and an exciting future in the era of emerging effective medical therapies and integration of effective medical therapies with metabolic surgeryMichail Kokkorakis, Angeliki Katsarou, Niki Katsiki, et al.
Biomedicines|May 25, 2024
Signatures and Discriminative Abilities of Multi-Omics between States of Cognitive DeclineFilippos Anagnostakis, Michail Kokkorakis, Keenan A Walker, et al.
Diabetes Research and Clinical Practice|January 27, 2026
Glucagon-like peptide-1 receptor agonists risk for anxiety and depression risk, and suicidality: a large cohort studyFilippos Anagnostakis, Michail Kokkorakis, Georgia Anastasiou, et al.
Diabetes, Obesity & Metabolism|November 27, 2025
Comparative effectiveness of SGLT2 sodium-glucose cotransporter-2 inhibitors and GLP-1 glucagon-like peptide-1 receptor agonists for incident dementia: A retrospective multicohort studyFilippos Anagnostakis, Michail Kokkorakis, Shrihari Nagarajan, et al.
Pharmacological Reviews|September 20, 2024
<b>Emerging Pharmacotherapies for Obesity: A Systematic Review</b>Michail Kokkorakis, Marlene Chakhtoura, Caline Rhayem, et al.
Metabolism: Clinical and Experimental|October 13, 2024
GDF-15 improves the predictive capacity of steatotic liver disease non-invasive tests for incident morbidity and mortality risk for cardio-renal-metabolic diseases and malignanciesMichail Kokkorakis, Pytrik Folkertsma, José Castela Forte, et al.
Endocrine Reviews|July 15, 2026
MASLD and the Cardiovascular-Kidney-Liver-Metabolic syndromeAngeliki M Angelidi, Chrysoula Boutari, Michail Kokkorakis, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|February 14, 2026
Long-term Risk of Prediabetes and Type 2 Diabetes Following SARS-CoV-2 Infection: A Nationwide Cohort StudyFilippos Anagnostakis, Michail Kokkorakis
Metabolism: Clinical and Experimental|October 31, 2024
The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservationKonstantinos Stefanakis, Michail Kokkorakis, Christos S Mantzoros
International Journal of Molecular Sciences|June 10, 2023
Impact of Solute Carrier Transporters in Glioma Pathology: A Comprehensive ReviewFilippos Anagnostakis, Michail Kokkorakis, Mariam Markouli, et al.
Metabolism: Clinical and Experimental|September 9, 2023
Milestones in the journey towards addressing obesity; Past trials and triumphs, recent breakthroughs, and an exciting future in the era of emerging effective medical therapies and integration of effective medical therapies with metabolic surgeryMichail Kokkorakis, Angeliki Katsarou, Niki Katsiki, et al.
Biomedicines|May 25, 2024
Signatures and Discriminative Abilities of Multi-Omics between States of Cognitive DeclineFilippos Anagnostakis, Michail Kokkorakis, Keenan A Walker, et al.
Diabetes Research and Clinical Practice|January 27, 2026
Glucagon-like peptide-1 receptor agonists risk for anxiety and depression risk, and suicidality: a large cohort studyFilippos Anagnostakis, Michail Kokkorakis, Georgia Anastasiou, et al.
Diabetes, Obesity & Metabolism|November 27, 2025
Comparative effectiveness of SGLT2 sodium-glucose cotransporter-2 inhibitors and GLP-1 glucagon-like peptide-1 receptor agonists for incident dementia: A retrospective multicohort studyFilippos Anagnostakis, Michail Kokkorakis, Shrihari Nagarajan, et al.
Pharmacological Reviews|September 20, 2024
<b>Emerging Pharmacotherapies for Obesity: A Systematic Review</b>Michail Kokkorakis, Marlene Chakhtoura, Caline Rhayem, et al.
Metabolism: Clinical and Experimental|October 13, 2024
GDF-15 improves the predictive capacity of steatotic liver disease non-invasive tests for incident morbidity and mortality risk for cardio-renal-metabolic diseases and malignanciesMichail Kokkorakis, Pytrik Folkertsma, José Castela Forte, et al.
Endocrine Reviews|July 15, 2026
MASLD and the Cardiovascular-Kidney-Liver-Metabolic syndromeAngeliki M Angelidi, Chrysoula Boutari, Michail Kokkorakis, et al.
Pageof 3